M.H.A.M
2 microdeletion gene Mrpl40 disrupts short-term synaptic plasticity and working memory through dysregulation of mitochondrial calcium
As for the FCC, the main concern for telehealth appears to be making sure rural areas places that are less likely to have doctors have access to telemedicine
Case 1 Male patient died while receiving semaglutide report invalidated because call-center contractors claimed patient identifier was missing (FDA found it in source documents) Case 2 Consumer taking liraglutide suffered a disabling stroke report cancelled because the consumer said it was unrelated to the drug Case 3 Patient taking semaglutide became depressed and committed suicide no follow-up attempts documented, still not submitted to FDA as of March 2026 Case 4 Consumer reported suicidal ideation on semaglutide in December 2024 not reviewed until February 2025, only after FDA inspectors flagged it Case 5 FDA found Novo Nordisk's written procedures allowed adverse events to be rejected based on causality assessments contradicting federal reporting requirements A Second Front: Vision Loss Claims Beyond the GI injury cases, a second GLP-1 MDL was created in December 2025 for vision loss claims
For many people, stopping too soon can lead to weight regain
Secondly, GLP-1 receptor agonists carry important safety considerations including risk of pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (based on rodent studies, though human relevance remains uncertain)
Specials" loading="lazy"/>
